Traditional cancer treatments include surgery, radiation, and chemotherapy. In recent years, however, cancer immunotherapy has achieved major success in the fight against cancer, through deliberate and specific enhancement of the natural immune system. Both active and passive immunotherapies have proven efficacious against various cancer types by increasing the anti-cancer immune capabilities or limiting the tumor evasion. Chimeric antigen receptor (CAR) therapy is active immunotherapy aimed at educating the patients' immune system to recognize and fight cancer. Checkpoint inhibitors are passive immunotherapy aimed at attenuation of inhibitory T cells, leading to the active status of effector cancer-fighting T cells.
With the application of nano medical engineering, Go-AI will focus on combination cancer therapy by delivering immunotherapy drugs which include Immune checkpoint inhibitors. Go-AI will initially focus on identifying the most effective Checkpoint inhibitors.
Immunotherapy drugs called immune checkpoint inhibitors work by blocking checkpoint proteins from binding with their partner proteins. This prevents the “off” signal from being sent, allowing the T cells to kill cancer cells.
Level 1, 237 East Boundary Road
Bentleigh East, Victoria, 3165
Australia
Email: contact@go-ai.com.au